Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEARCH: Atorvastatin in Arrhythmogenic Cardiomyopathy
NCT06922994Phase 2Recruiting
- Sponsor
- Centro Cardiologico Monzino
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arrhythmogenic cardiomyopathy (ACM) comparing Atorvastatin with Placebo (2 arms). Primary endpoint: Efficacy of Atorvastatin in avoiding functional right ventricular deterioration at 18 months. Started Mar 2025; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
arrhythmogenic cardiomyopathy (ACM)
Beyond the preview
Go deeper on NCT06922994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922994.